Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659358 · ClinicalTrials.gov registry record
Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer
A clinical trial, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- 37
- Enrollment target
NCT02659358: Completed study, sponsored by Cedars-Sinai Medical Center.
NCT02659358 is a clinical trial that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02659358 has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the association between wearable biosensor data, performance status and patient-reported outcomes in cancer patients. Participants in this study will wear a biosensor (Fitbit Charge HR®) for 15 days and respond to questionnaires that will assess patient reported outcome measures including physical function, emotional distress, pain interference, sleep disturbance and fatigue. Eligible patients will have a diagnosis of advanced cancer. Patients must be greater than 18 years of age and be English speaking due to the questionnaires that will be administered during the study. Patients must also be ambulatory (use of walking aids, such as cane and rollator, is acceptable) and have access to a smartphone with internet access (IOS or Android). It is also necessary for patients to have scheduled oncology clinic visits at least once every 2 weeks.
Primary Outcome
Data will be compared to reference standards to answer primary objective.
Interventions
- DEVICE Fitbit Charge HR®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2016-01-24 |
| Est. Completion | 2017-08-24 |
What the finished NCT02659358 record still lists
NCT02659358 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Fitbit Charge HR® is the first listed.
NCT02659358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02659358 about?
NCT02659358 is a clinical study titled "Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer". The purpose of this study is to evaluate the association between wearable biosensor data, performance status and patient-reported outcomes in cancer patients. Participants in this study will wear a biosensor (Fitbit Charge HR®) for 15 days and respond to questionnaires that will assess patient repor...
What is the current status of trial NCT02659358?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2016-01-24. Estimated completion is 2017-08-24.
What interventions are being tested in trial NCT02659358?
The interventions under investigation include: Fitbit Charge HR® (DEVICE).
Who is sponsoring clinical trial NCT02659358?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI